Cefepime + Tazobactam Injection

Cefepime + Tazobactam Injection

Cefepime + Tazobactam Injection

  • Packing: Vial
  • Available Strength : 1.125 Gm

Description

Product Description: Cefepime + Tazobactam Injection is a potent combination of cefepime, a fourth-generation cephalosporin antibiotic, and tazobactam, a beta-lactamase inhibitor. This combination therapy offers enhanced efficacy against a broad spectrum of bacterial infections, including those caused by multidrug-resistant organisms. Cefepime + Tazobactam is specifically formulated to overcome bacterial resistance mechanisms, providing a comprehensive approach to treating complex infections.

Indications and Usage: Cefepime + Tazobactam Injection is indicated for the treatment of moderate to severe bacterial infections caused by susceptible organisms. It is commonly prescribed for infections of the respiratory tract, urinary tract, skin and soft tissue, intra-abdominal infections, septicemia, and bacterial meningitis.

Dosage and Administration: Dosage and administration should be determined by a qualified healthcare professional based on factors such as the severity of the infection, the patient's age and weight, and the susceptibility of the causative bacteria. Cefepime + Tazobactam is typically administered intravenously at intervals ranging from every 8 to 12 hours.

Dosage Forms and Strengths: Cefepime + Tazobactam Injection is available as a sterile powder for reconstitution in various strengths, typically ranging from 1.125 grams to 4.5 grams per vial.

Contraindications: Cefepime + Tazobactam Injection is contraindicated in patients with known hypersensitivity to cephalosporin antibiotics, beta-lactamase inhibitors, or any component of the formulation. It should not be used in patients with a history of severe allergic reactions to penicillin or other beta-lactam antibiotics.

Warnings and Precautions: Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of cefepime + tazobactam. It should be used with caution in patients with a history of allergies, asthma, or other allergic conditions. Prolonged use may result in the overgrowth of non-susceptible organisms, including fungi. Clostridium difficile-associated diarrhea has been reported with the use of nearly all antibacterial agents, including cefepime + tazobactam.

Adverse Reactions/Side Effects: Common adverse reactions associated with cefepime + tazobactam include diarrhea, nausea, vomiting, rash, and injection site reactions. Serious adverse reactions may include severe allergic reactions, Clostridium difficile-associated diarrhea, and hepatic dysfunction.

Drug Interactions: Cefepime + Tazobactam may interact with other medications, including aminoglycosides, which may potentiate nephrotoxicity. Concurrent use with loop diuretics may increase the risk of nephrotoxicity. Caution should be exercised when co-administering with other nephrotoxic drugs.

Use In Specific Populations Description: Use of cefepime + tazobactam in pregnant women should be weighed against the potential risks to the fetus. It is excreted in breast milk; caution should be exercised when administering to nursing mothers. Safety and effectiveness in pediatric patients have been established for certain indications and age groups.

Clinical Pharmacology: Cefepime exerts its bactericidal effects by interfering with bacterial cell wall synthesis, leading to cell death. Tazobactam inhibits the action of beta-lactamase enzymes, thereby protecting cefepime from degradation and extending its antibacterial spectrum.

How Supplied/Storage and Handling: Cefepime + Tazobactam Injection is supplied as sterile powder in single-dose vials. It should be stored at controlled room temperature (20°C to 25°C) and protected from light.